Chembio Diagnostics, Inc. announced that it has received a CE mark for its diagnostic test developed in collaboration with AstraZeneca. Chembio and AstraZeneca have collaborated to develop a quantitative diagnostic test to detect an undisclosed biomarker, using Chembio’s patented DPP® platform. The CE marked DPP® System, which includes the new DPP® test and DPP® Micro Reader, provides quantitative results in ten minutes from a small drop of fingertip or venous blood.